Altimmune Announces Initiation Of 48-week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity
Altimmune, Inc. (NASDAQ:ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
Altimmune Q4 EPS $(0.57) Beats $(0.65) Estimate
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.65) by 12.31 percent. This is a 235.29 percent decrease over losses of $(0.17) per share from the
Earnings Scheduled For March 14, 2022
Companies Reporting Before The Bell
• F45 Training Holdings (NYSE:FXLV) is projected to report earnings for its fourth quarter.
The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb’s Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings
Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments served as catalysts during the week.
Altimmune’s Mid-Stage Pemvidutide Study Cleared By FDA For Obesity
The FDA has cleared Altimmune Inc's (NASDAQ:
52 Biggest Movers From Yesterday
Gainers
Paltalk, Inc. (NASDAQ: PALT) shares jumped 60.1% to close at $8.39 on Wednesday.